Top Markets
Coin of the day
COSCIENS Biopharma Inc. COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc.

CSCI
Rank in Stocks #34152
COSCIENS Biopharma Inc., a life science company, develops and commercializes... COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Share Price
$5.78
Last synced: 2026-08-14
Market Cap
$6.14M
Change (1 day)
0.25%
Change (1 year)
-32.55%
Country
CA
Trade COSCIENS Biopharma Inc. (CSCI)

Category

EPS for COSCIENS Biopharma Inc. (CSCI)
EPS as of 2026 TTM: 0
According to COSCIENS Biopharma Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for COSCIENS Biopharma Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors